Request Trial
shutterstock_1349383838_thomas_quack
Thomas Quack / Shutterstock.com
22 October 2019AmericasSarah Morgan

CRISPR Therapeutics to buy JV from Bayer

A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Merchant & Gould hires 13 attorneys to open new Boston office
6 January 2026   The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.
Americas
PTAB year in review: A shifting landscape and outlook for 2026
2 January 2026   With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.
Americas
5 ways the USPTO director is changing US innovation
24 December 2025   John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

More features

Merchant & Gould hires 13 attorneys to open new Boston office
Novo Nordisk secures China win ahead of key patent expiration
Edwards v Meril: Inside the UPC’s landmark medtech showdown
Bird & Bird targets Nordic life sciences growth with regulatory hire
PTAB year in review: A shifting landscape and outlook for 2026
UPC: A review of 2025 and what to expect in 2026
Mental health in IP: ‘We have a clear picture of the problem’
From Edwards to Insulet: Three key medical device cases of 2025